(Luisa Gonzalez/REUTERS)
During the Great Embryonic Stem Cell Debate, circa 2001-2008, I watched the scientistsblatantly lie about the supposedly low potential for adult stem cells and the CURES! CURES! CURES that were just around the corner from embryonic stem cells. You remember: Children would soon be out of their wheelchairs and Uncle Ernies Parkinsons would soon be a disease of the past.
The pro-ESCR campaign was filled with so much disinformation and hype willingly swallowed by an in-the-tank media all in a corrupt attempt to overturn the minor federal funding restrictions over ESCR imposed by the president, and to hurt President Bush politically.
After the Bush presidency, the issue became quiescent. And now, it turns out that the clinical advances that have been made are not from embryonic stem cells.
During the debate, David A. Prentice a stem-cell researcher and my good friend took a sabbatical from his Indiana State University professorship to tout the great potential of adult stem cells (and to oppose human cloning) around the world. He became quite prominent in the debate for which he was punished by his universitys administration. For example, despite receiving teaching awards, he was moved from graduate classes and his lab privileges were curtailed.
Prentice eventually headed for The Swamp to continue his advocacy. He is now with the Charlotte Lozier Institute, where he has continued to track and educate about stem-cell science and engage policy controversies.
Prentice just published a major peer-reviewed article in the science journal Circulation Research, in which he details the amazing successes of adult stem-cell research demonstrating that the ESCR hypers had it wrong and he had it right.
Prentice outlines the many problems that make embryonic stem cells ill suited for clinical use, including the difficulty ofdifferentiating and integrating ES cells into the body, the problem that these cells have shown evidence of causing arrhythmia, the potential to cause tumors, and immunogenicity, in real peoples language, rejection caused by triggering the bodys immune response.
In contrast, ethical stem cells have had excellent successes. For example, induced pluripotent stem cells, which can be made from normal skin cells, are splendid for use in cell modeling and drug testing.
But Prentices primary focus is on adult stem cells, often taken from donor bone marrow or a patients own body. They have also not advanced as fast as was hoped, but they are progressing into clinical uses and human studies. From, Adult Stem Cells:
Not only do adult stem cells carry no ethical baggage regarding their isolation, their practical advantages over pluripotent stem cells have led to many current clinical trials, as well as some therapies approved through all phases of Food and Drug Administration testing.
Peer-reviewed, published successful results abound, with numerous papers now documenting therapeutic benefit in clinical trials and progress toward fully tested and approved treatments. Phase I/II trials suggest potential cardiovascular benefit from bone marrowderived adult stem cells and umbilical cord bloodderived cells.
Striking results have been reported using adult stem cells to treat neurological conditions, including chronic stroke. Positive long-term progression-free outcomes have been seen, including some remission, for multiple sclerosis, as well as benefits in early trials for patients with type I diabetes mellitus and spinal cord injury. And adult stem cells are starting to be used as vehicles for genetic therapies, such as for epidermolysis bullosa.
If this progress had been derived from embryonic stem cells, the headlines would have been deafening. The cheering from the media would include anchors dancing with pom-poms!
But the media isnt much interested in reporting adult stem-cell successes prominently because doing so doesnt promote favored ideological agendas. Thats not good journalism.
Prentice concludes:
The superiority of adult stem cells in the clinic and the mounting evidence supporting their effectiveness in regeneration and repair make adult stem cells the gold standard of stem cells for patients.
Thats excellent news for everyone, and may it continue.
But as we benefit from these ethical treatments, the next time ideologically driven scientists, bioethicists, and their media water carriers seek to drive public opinion on scientific issues in a partisan direction by deploying the propaganda tools of hype, exaggeration, and castigation of those who espouse heterodox views, remember how the Great Stem Cell Debate turned out.
See original here:
Stem Cells & David A. Prentice -- Adult Stem Cells Are Now ...
- Brenner and Rector's The Kidney, 2-Volume Set. Edition No. 11 - ResearchAndMarkets.com - Associated Press - December 6th, 2019
- Stem Cells Market to a Revenue Opportunity of US$270.5 bn During the Period from 2025 - News Description - December 6th, 2019
- Stem cell Therapy Market 2019-2027| Business Scope and Investment Analysis By MEDIPOST, PHARMICELL Co., Ltd, Holostem Terapie Avanzate Srl, Mesoblast... - December 6th, 2019
- Cutting Through the Headlines: Are Scientists Really Growing Sentient "Mini-brains"? - Technology Networks - December 6th, 2019
- Year in Review: Respiratory Infection - MedPage Today - December 6th, 2019
- Whats Happening: IDF Shabbat of Heroes, Sephardic Papers - Jewish Journal - December 5th, 2019
- Global Stem Cells Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2025 - Breaking News Updates - December 5th, 2019
- Marine Coatings Market is Anticipated to Register a Value of XX Million by the end of 2017 - 2025 - Markets Gazette 24 - December 5th, 2019
- Stem Cell Market 2019 | What Will Be the Market Size and the Growth Rate Analysis by 2026? - Hitz Dairies - December 3rd, 2019
- Stem Cells Market is Expected to Register a Healthy CAGR of 13.8% During the Period from 2017 to 2025 - Statsflash - December 3rd, 2019
- BrainStorm Cell Therapeutics to make scientific presentations at the 30th International Symposium on ALS/MND - BioSpace - November 28th, 2019
- Inside the Beltway: Abortion, immigration among forbidden topics at Thanksgiving table - Washington Times - November 28th, 2019
- Canine Stem Cell Therapy Market Value Projected to Expand by 2026 - The Hilltop Monitor - November 28th, 2019
- Global Stem Cells Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2025 - Industry News Info - November 28th, 2019
- Stem Cell Banking Market Size, Share, Growth, Future Prospects, Competitive Analysis and Forecast To 2026 - Med News Ledger - November 28th, 2019
- Lulu and Nana are the result of a defiant experiment in human gene modification - The Irish Times - November 28th, 2019
- Types of Adult Stem Cells - Stem Cell Institute - November 26th, 2019
- Adult Leukemia: What You Need to Know - Dana-Farber Cancer Institute - November 26th, 2019
- Hatching disease in a dish: The new frontier in drug testing - Maclean's - November 26th, 2019
- Bedfordshire Police officer reunited with woman whose life he saved through stem cell donation - Bedford Today - November 26th, 2019
- BrainStorm Cell Therapeutics to make scientific presentations at the 30th International Symposium on ALS/MND - GlobeNewswire - November 26th, 2019
- Bedfordshire Police officer reunited with stem cell recipient - Cranfield and Marston Vale Chronicle - November 26th, 2019
- Keeping cells alive | Interviews - The Naked Scientists - November 26th, 2019
- Dana-Farber joins with leading Boston teaching hospitals and universities - Mirage News - November 26th, 2019
- Applying AI and CRISPR to stem cells to improve regenerative medicine - FierceBiotech - November 20th, 2019
- Decoding the building blocks of life: bit bio races toward a sustainable source of human cells - Proactive Investors UK - November 20th, 2019
- 1st SCD Trial Patient Shows CTX001 Gene Editing to be Safe, Effective - Sickle Cell Anemia News - November 20th, 2019
- CStone announces first patient dosed in the Phase I bridging registrational study of ivosidenib - BioSpace - November 20th, 2019
- Novocure Announces 43 Presentations on Tumor Treating Fields at 24th Annual Meeting of the Society for Neuro-Oncology - Arizona Daily Star - November 20th, 2019
- Maltese abroad: the best-selling author with roots in Gozo - Times of Malta - November 20th, 2019
- Early Results Are Positive for Experimental CRISPR Therapies - The Scientist - November 19th, 2019
- CHMP recommends EMA approval of polatuzumab vedotin for the treatment of adult patients with R/R DLBCL - Lymphoma Hub - November 19th, 2019
- CStone announces first patient dosed in the Phase I bridging registrational study of ivosidenib - PRNewswire - November 19th, 2019
- Redding woman donates bone marrow, saves life of a father - FOX61 Hartford - November 16th, 2019
- Maxim Group Maintains Their Buy Rating on Brainstorm Cell Therapeutics (BCLI) - Smarter Analyst - November 16th, 2019
- How 3D Printing Is Turning Each And Every Industry On Its Head - SafeHaven.com - November 16th, 2019
- BIORESTORATIVE THERAPIES, INC. (OTCMKTS:BRTX) Files An 8-K Submission of Matters to a Vote of Security Holders - Market Exclusive - November 16th, 2019
- Global Cell Expansion Market 2019 is predicted to reach an excellent valuation of by 2024 - Galus Australis - November 16th, 2019
- Stem Cell Assay Market is Growing Massively in Upcoming Year with Top Key Players like GE Healthcare, Thermo Fisher Scientific Inc., Merck KGaA, Cell... - November 15th, 2019
- Bone marrow transplant: What it is, uses, risks, and recovery - Medical News Today - November 15th, 2019
- The Demand of Mesenchymal Stem Cells Market Research Report 2019 Future Growth, Demand, Application, Trends, Vendor Landscape, Industry Insight,... - November 15th, 2019
- BrainStorm Cell Therapeutics Announces Research Grant Award From the National Multiple Sclerosis Society - Yahoo Finance - November 14th, 2019
- BrainStorm Announces Financial Results for the Third Quarter of 2019 and Provides a Corporate Update - GlobeNewswire - November 14th, 2019
- BrainStorm Cell Therapeutics Announces Ralph Kern MD MHSc to Present at the 7th International Stem Cell Meeting - Yahoo Finance - November 14th, 2019
- INDIA Indian doctor: Medical innovation should not try to replace the Creator - AsiaNews - November 14th, 2019
- iCell Gene Therapeutics Announces CAR-T Oral and Poster Presentations at 61st American Society of Hematology Annual Meeting - Send2Press Newswire - November 14th, 2019
- Contrasting BioRestorative Therapies (OTCMKTS:BRTX) and Livongo Health (OTCMKTS:LVGO) - DFS Caller - November 14th, 2019
- Phase 3 Trial of NINLAROTM (ixazomib) as First Line Maintenance Therapy Met Primary Endpoint in Multiple Myeloma Patients not treated with Stem Cell... - November 12th, 2019
- Army veteran to save woman with blood cancer through stem cell donation - Stoke-on-Trent Live - November 12th, 2019
- Financial Contrast: BioRestorative Therapies (OTCMKTS:BRTX) and Livongo Health (OTCMKTS:LVGO) - DFS Caller - November 12th, 2019
- Autolus Therapeutics Plc (AUTL) Q3 2019 Earnings Call Transcript - The Motley Fool - November 9th, 2019
- Stem Cell Therapy Market Trends, Secondary Research With Geron Corporation, Vericel Corporation, Pluristem Therapeutics, Cytori Therapeutics, Fate... - October 29th, 2019
- Huntington's Marked by Inflammation and Changes in Brain's Striatum Before Symptoms, Study Finds - Huntington's Disease News - October 29th, 2019
- In 2030, Our Protein Will Come From a Laband We'll All Be Better Off For It - Singularity Hub - October 28th, 2019
- NASA plans to cut cost of space exploration by commercializing low-earth orbit - Digital Trends - October 27th, 2019
- BrainStorm Cell Therapeutics to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference - BioSpace - October 27th, 2019
- Artificial Early Mouse Embryos Created In The Lab Using Stems Cells Rather Than Sperm Or Eggs - IFLScience - October 21st, 2019
- Healthcare Terms Are Out of Touch, Says Mom Advocate - Medscape - October 21st, 2019
- A stop-motion movie of the whole brain, starring new neurons - Spectrum - October 21st, 2019
- Humans evolved to think faster by slowing down brain development - New Scientist News - October 21st, 2019
- Stem Cell Banking Market was valued at $1986 million in 2016 - Markets Gazette - October 19th, 2019
- Republicans demand answers about government experiments with animals and fetal tissue - Washington Examiner - October 17th, 2019
- The Other Side of Stem Cell Research - The Tablet Catholic Newspaper - October 17th, 2019
- Reviewing MediciNova Inc. (MNOV)'s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)'s results - MS Wkly - October 17th, 2019
- SI-BONE Inc. (SIBN) and Cesca Therapeutics Inc. (NASDAQ:KOOL) Comparing side by side - MS Wkly - October 17th, 2019
- Inherited Learning? It Happens, but How Is Uncertain - Quanta Magazine - October 17th, 2019
- Contrasting of Brainstorm Cell Therapeutics Inc. (BCLI) and Magenta Therapeutics Inc. (NASDAQ:MGTA) - MS Wkly - October 17th, 2019
- Stem Cells Market to Gain Huge Traction Owing to Arrival of New-Fangled Treatments for Long-Lasting Sicknesses Till 2025 | Million Insights - P&T... - October 7th, 2019
- New Tools in the Works to Probe Adult Human Neurogenesis - The Scientist - October 7th, 2019
- Follow the lead of Aston Villa players and become a blood stem cell donor - 7500 To Holte - October 7th, 2019
- Starving Cancer by Cutting Off Its Favorite Foods, Glucose and Glutamine - American Council on Science and Health - October 6th, 2019
- We're making tiny brains in the lab should we be worried for them? - CBC.ca - October 6th, 2019
- Female Scientist To Lead Advanced Cancer Research Project In Space - SheThePeople - October 6th, 2019
- Cancer cells to be tested in zero gravity on Chinese Space Station - E&T Magazine - October 4th, 2019
- Bone Therapeutics to present preclinical data on the osteogenic properties of ALLOB in bone repair at 27th Annual Meeting of the European Orthopaedic... - October 4th, 2019
- Global Stem Cell Therapy Market Report, 2019-2030 : Focus on Treatment Type, Cell Source, Indication and Competitive Landscape - Space Market Research - October 4th, 2019
- Genmab Announces U.S. FDA Approval of DARZALEX (daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone for Frontline Multiple... - September 27th, 2019
- The unexpected functional diversity of reactive astrocytes - Baylor College of Medicine News - September 27th, 2019
- Troy resident 'gets it done' with ground-breaking treatment - Troy Daily News - September 27th, 2019
- Stem Cell Assay Market Overview by Industry Chain Information, Upstream Raw Materials & Downstream Industry 2017 2025 - Herald Space - September 27th, 2019